Edgepark | Omnipod

Omnipod^® 5

The first wearable, on-body, tubeless, automated insulin delivery system¹. The Omnipod 5 System consists of a tubeless insulin Pod and the Omnipod® 5 App on an Insulet-provided Controller or installed on a compatible smartphone.^*

Indicated for use by individuals with Type 1 diabetes mellitus who are 2 years of age and older¹
Full smartphone control for patients with compatible smartphones^2,3
Omnipod 5 App allows you to select a basal profile, target glucose and bolus settings, activate and deactivate the Pod, connect with the Dexcom G6^® Continuous Glucose Monitoring System, and select insulin delivery mode¹
Helps keep you in range, day and night^4,5
No multiple daily injections, tubes, or fingersticks⁶

Request Now

Omnipod DASH^®

A continuous insulin delivery system that includes a wearable, tubeless insulin Pod that’s controlled by a smartphone-like Personal Diabetes Manager (PDM). No multiple daily injections, and no mealtime math with built-in dosage calculations. The Pod can be worn almost anywhere you’d inject and carries up to 3 days– or 72 hours–of insulin.

Cleared for the management of diabetes mellitus for insulin-requiring people¹
PDM (Personal Diabetes Manager) displays up to 90 days of information, including basal rates, bolus doses, carbohydrates, alarms, and blood glucose entries ¹

Request Now

Title

First Name

Last Name

Date of Birth

Check here if you are filling out this form on behalf of another person.

Device Preference

E-mail

Phone Number

I agree that my information will be used as described on this page and in the Edgepark Notice of Privacy Practices

I agree to enroll to receive real-time order updates via text message/SMS. Terms & Conditions

I'm also interested in having Edgepark contact me to see if I qualify for Continuous Glucose Monitoring (CGM) supplies.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

^* To view compatable smartphones for the Omnipod^® 5, visit omnipod.com/current-podders/resources/omnipod-5/device-compatibility.

¹ Omnipod^® Product Information Guide, 2022.

² The Omnipod^® 5 System must be used with the Dexcom G6 mobile app and is not compatible with the Dexcom receiver. Dexcom compatible smart devices sold separately: www.dexcom.com/compatibility.

³ Dedicated Omnipod^® 5 handheld controller is also provided. Initial compatible smartphone devices to include select Samsung devices. A full list of compatible smartphone devices will be made available on www.omnipod.com upon receiving FDA clearance.

⁴ Study in 80 people with T1D aged 2 5.9 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%. Average time in Target Glucose range (6AM 12AM) from CGM in standard therapy vs Omnipod 5 = 58.2% vs. 64.3%. Average time in Tar get Glucose range (12AM 6AM) from CGM in standard therapy vs. Omnipod 5 = 60.6% vs 82.4%. Average overnight time (12AM 6AM) with high blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 32.1% vs. 20.7%; 42.2% vs. 20.7%. Average day time (6AM 12AM) with high blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 32.6% vs. 26.1%; 46.4% vs. 33.4%. Median overnight time (12AM 6AM) with low blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 2.07% vs. 0.82%; 0.78% vs. 0.78%. Media n day time (6AM 12AM) with low blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 1.91% vs. 1.08%; 1.17% vs. 1.62%. Average A1c in standard therapy vs. Omnipod 5 = 7.4% vs. 6.9%. Sherr JL, et al. Diabetes Care (2022).

⁵ Study in 240 people with T1D aged 6 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in adults/adolescents and children = 64.7% vs. 73.9%; 52.5% vs. 68.0%. Average day time (6AM 12AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.8% vs. 72.5%; 51.5% vs. 64.6%. Average overnight (12AM 6AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.3% vs. 78.1%; 55.3% vs. 78.1%. Average time with high blood glucose overnight from CGM in standard therapy vs. Omnipod 5 = 38.4% vs. 16.9%. Average time with high blood during daytime from CGM in standard therapy vs. Omnipod 5 = 39.7% vs. 33.7%. Average time with low blood glucose overnight from CGM in standard therapy vs. Omnipod 5 = 3.41% vs. 2.13%. Ave rage time with low blood glucose during daytime from CGM in standard therapy vs. Omnipod 5 = 3.44% vs. 2.57%. Average A1c in adults/adolescents and children, standard therapy vs. Omnipod 5 = 7.16% vs 6.78%; 7.67% vs 6.99%. Brown et al. Diabetes Care (2021).

Making Diabetes
Management Easier.

Select the Omnipod^® System that is best for you

Compare Omnipod® Systems

Interested in an Omnipod® System?

Making Diabetes Management Easier.

Select the Omnipod® System that is best for you

Compare Omnipod® Systems

Interested in an Omnipod® System?

Making Diabetes
Management Easier.

Select the Omnipod^® System that is best for you